Daniel T. Scavilla

President and Chief Executive Officer at GLOBUS MEDICAL

Board

Since April 2022

Age

59 years

Education

Holds a B.S. in Finance and Organizational Behavior from LaSalle University and an MBA in International Management from Temple University.

Tenure

Joined GMED in May 2015 as CFO, later served as Executive Vice President and President of Trauma, and has been serving as President and Chief Executive Officer since April 2022.

Also at GLOBUS MEDICAL

DCP

David C. Paul

Chairman of the Board and Executive Chairman

KWP

Keith W. Pfeil

Chief Operating Officer and Chief Financial Officer

KGH

Kelly G. Huller

Senior Vice President, General Counsel, and Corporate Secretary

About

Daniel T. Scavilla has had a long and varied career in the medical device industry, demonstrating a consistent ability to drive growth and innovation through strategic leadership initiatives.

Prior to his GMED tenure, he spent 28 years at a major healthcare corporation in various senior financial and operational roles, honing skills in financial management and business operations that have profoundly influenced his leadership style.

Outside of his primary role at GMED, his participation on boards and governance committees reflects a commitment to advancing healthcare technologies and ethical business practices, further cementing his reputation as a transformative leader in the industry.

$GMED Performance Under Daniel T. Scavilla

Past Roles

Organization	Role	Date Range	Details
Impulse Dynamics	Board of Directors	November 2021 – July 2023	Served on the board of a privately held medical technology company specializing in minimally invasive treatment for heart failure patients
Globus Medical	Chief Financial Officer	May 2015 – April 2022	Joined GMED as CFO prior to promotion to CEO
Globus Medical	Executive Vice President, Chief Commercial Officer, and President of Trauma	N/A – April 2022	Launched the Orthopedics and Trauma business unit at GMED
Johnson & Johnson	Chief Financial Officer, Global Vice President Finance & Business Operations of J&J Vision	N/A	Oversaw a business with $4 billion in annual global revenue
Johnson & Johnson	Chief Financial Officer, Worldwide Vice President Finance of Advanced Sterilization Products	N/A	Led the infection prevention business within the MedTech unit
Johnson & Johnson - McNeil Consumer Healthcare (now Kenvue)	Financial Management	N/A	Held financial management roles
Johnson & Johnson - Centocor Biologics	Financial Management	N/A	Held financial management roles
Janssen Pharmaceutical (Cilag Schaffhausen Operations)	Financial Management	N/A	Held financial management roles in Switzerland

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$463,500	Annually in 2023	Fixed base salary
Bonus	$150,000	One-time in 2023	Awarded in recognition of the successful NuVasive acquisition closing
All Other Compensation	$32,980	Annually in 2023	Comprises group health insurance benefits ($16,812 for group health insurance ), Company 401(k) plan matching, vehicle allowance, YMCA membership reimbursement, and insurance premiums

Performance Compensation

Data from FY 2023

Annual Non-Equity Incentive Plan

Metric [USD Millions/Percent]**	Details
Revenue Goal	$1,125
Threshold (0% Payout)	75% or less of the revenue goal
Target (100% Payout)	97.5% of revenue goal resulting in a target payout of $900,000
Maximum (145% Payout)	110% of revenue goal
Actual Revenue Performance	$1,154 million (102.6% of goal)
Final Payout Rate	113.5% of the target amount
Evaluation Period	2023, with payout disbursed in February 2024
Weight	Not explicitly stated; revenue is the sole metric (implied 100%)

Option Awards

Grant Date	Options Granted	Grant Date Fair Value	Grant Date Stock Price	Vesting Schedule
January 26, 2023	100,000	$2,687,936	$75.18 per share	Vesting over 4 years: 1/4 vesting on January 1, 2024; remaining options vest ratably monthly over 36 months
October 10, 2023	10,000	$208,458	$53.02 per share	Vesting over 4 years: 1/4 vesting on September 1, 2024; remaining options vest ratably monthly over 36 months